Diamedica Therapeutics Inc. · NASDAQ:DMAC

Diamedica Therapeutics — Technical Presentation (July 2025)

21 slides from Diamedica Therapeutics's technical presentation, Jul 17, 2025

  1. Slide 1: Interim Phase 2 (Part 1a) Preeclampsia Data

    Interim Phase 2 (Part 1a) Preeclampsia Data July 17, 2025 Transforming Care for Preeclampsia and Stroke

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and forward-looking information that are based on the beliefs of management and reflect management’s current expe

  3. Slide 3: Early-Onset PE and FGR: Severe Conditions with a $5B+ U.S. Market

    Early-Onset PE and FGR: Severe Conditions with a $5B+ U.S. Market Disease Overview Annual Incidence in U.S. 〉Preeclampsia (PE): life-threatening high blood pressure disorder accompanied 325,000+ by multi-system organ damage that FGR & PE1,2 occurs only during pregnancy. – Early onset PE is a severe

  4. Slide 4: Interim Phase 2 (Part 1a) Results

    Interim Phase 2 (Part 1a) Results

  5. Slide 5: Interim Phase 2 (Part 1a) Results of DM199 for Preeclampsia are a Clear Success

    Interim Phase 2 (Part 1a) Results of DM199 for Preeclampsia are a Clear Success 〉 Safety: No placental transfer of DM199. Well tolerated with no serious TEAEs reported. 〉 Blood Pressure (BP): Dose-dependent reductions in both systolic (SBP) and diastolic (DBP) o Cohort 9 (n=3; highest dose): Achieve

  6. Slide 6: DM199 Preeclampsia Phase 2 IST Trial – Part 1a

    Part 1 Overview DM199 Preeclampsia Phase 2 IST Trial – Part 1a 〉 27-42 weeks gestation (singleton) Women planned for delivery within 72 hours 〉 >150 systolic blood pressure 〉 Receiving standard of care Part 1a- Dose Escalation (3x3 Design) 〉 <72 hours scheduled for delivery C9 2.0µg/kg IV + 12.0µg/k

  7. Slide 7: DM199 Administration Timepoints and Prespecified BP Measurements

    DM199 Administration Timepoints and Prespecified BP Measurements Timepoints of BP Measurements Approximate Tmax of IV and SC Doses Time After IV is Completed + 5 Min + 30 Min + ~1hr …… + 24hr Participant Meets DM199 Screening Requirement SC (ie SBP >150 mmHg), is Consented, and Enrolled DM199 IV Inf

  8. Slide 8: Baseline Demographics

    Baseline Characteristics DM199 (n=28) Demographics Median (IQR) gestation at enrollment (weeks + days) 37+0 (35+6 - 38+1) Median (IQR) maternal age (years) 32.5 (28.8 - 36.3) Mean (SD), birth weight in grams 2591.3 (553.4) BMI, median (IQR) 36.8 (33.4 - 43.4) Race, n(%) Black 22 (79) Mixed 6 (21) Me

  9. Slide 9: Delivery Characteristics

    Delivery Characteristics Characteristics DM199 n(%) Vaginal delivery 9 (32) Cesarean section 19 (68) Time to delivery <2 hours 1 (4) <4 hours 3 (11) <8 hours 9 (32) 〉~80% of <12 hours 16 (57) deliveries <24 hours 22 (79) occurred within ≥24 hours 6 (21) 24 hours Received balloon catheter 14 (50) Rec

  10. Slide 10: DM199 Was NOT Detected in Umbilical Cord Blood in Any Dose Cohort

    DM199 Was NOT Detected in Umbilical Cord Blood in Any Dose Cohort 〉 At delivery, DM199 was not detected in any cord blood samples, while a clear dose-dependent increase in DM199 was observed in maternal plasma. 〉 Data suggests DM199 does not cross the placental barrier, a potentially unique safety a

  11. Slide 11: DM199 Was Generally Safe and Well Tolerated

    DM199 Was Generally Safe and Well Tolerated 〉No serious TEAEs were reported in response to any dose Maternal Treatment-Emergent Adverse Events TEAE N=28 [n(%)] Dose Cohorts Nausea 4 (14%) C8 (n=2), C9 (n=2) Headache 3 (11%) C3 (n=1), C6 (n=2) Flushing 2 (7%) C6 (n=1), C9 (n=1) 〉No events of hypotens

  12. Slide 12: Blood Pressure Was Reduced at Prespecified 5-Minute Post-Infusion Endpoint

    Blood Pressure Was Reduced at Prespecified 5-Minute Post-Infusion Endpoint Pooled Cohorts C6–C9 achieved statistically significant reductions in SBP (-25 mmHg) and DBP (-13 mmHg) Systolic Diastolic Cohorts 6 – 9 10 Cohorts 6 – 9 5 Dose Range For Further Clinical Investigation Dose Range For Further

  13. Slide 13: Blood Pressure Was Reduced at Prespecified 30-Minute Post-Infusion Endpoint

    Blood Pressure Was Reduced at Prespecified 30-Minute Post-Infusion Endpoint Pooled Cohorts C6–C9 achieved statistically significant reductions in SBP (-15 mmHg) and DBP (-13 mmHg) Systolic Diastolic 5 Cohorts 6 – 9 Cohorts 6 – 9 Dose Range For Further Clinical Investigation Dose Range For Further Cl

  14. Slide 14: DM199 Drove Statistically Significant Systolic Blood Pressure Reduction

    DM199 Drove Statistically Significant Systolic Blood Pressure Reduction Pooled Analysis of Cohorts 6 to 9 1.0-2.0 μg/kg IV (Cohorts 6-9) n=122 Systolic Blood Pressure 175 170 165 167 Severe hypertension (AJOG) Average1 SBP (mmHg) 160 -15 -14 -17 -18 155 -22 -20 150 -25 152** 153** 149** 150** 145 14

  15. Slide 15: DM199 Drove Statistically Significant Diastolic Blood Pressure Reduction

    DM199 Drove Statistically Significant Diastolic Blood Pressure Reduction Pooled Analysis of Cohorts 6 to 9 1.0-2.0 μg/kg IV (Cohorts 6-9) n=122 Diastolic Blood Pressure 110 105 104 Average1 DBP (mmHg) 100 -11 -10 -13 -13 -13 -13 95 -17 94** 94* 90 91** 92** 91** 91** 85 88** 80 (p=0.0007) (p=0.0002)

  16. Slide 16: DM199 Reduced Uterine Artery Resistance, Suggesting Enhanced Placental Perfusion

    DM199 Reduced Uterine Artery Resistance, Suggesting Enhanced Placental Perfusion Overall1,2 (n=25) 2.5 2 2 〉Dilation of the uterine arteries was assessed by Doppler ultrasound at baseline and two hours after Uterine Artery Pulsatility Index Reduced blood flow resistance Cohorts 1&2 1.5 Cohort 3 IV i

  17. Slide 17: Summary Remarks

    Summary Remarks DM199 is emerging as an exciting potential therapeutic option for both preeclampsia and fetal growth restriction DM199 appears to be generally well tolerated across broad exposure levels, and does not cross the placental barrier Early signals of improved placental perfusion suggest t

  18. Slide 18: Next Steps for the Phase 2 Trial

    Next Steps for the Phase 2 Trial

  19. Slide 19: Next Phases of Preeclampsia IST Following Part 1A Completion

    Next Phases of Preeclampsia IST Following Part 1A Completion All parts can enroll concurrently Part 1b (n=30) Part 2 (n=30) Part 3 (n=30) Planned Delivery in 72 Hrs. Expectant Management Fetal Growth Restriction  Recruiting the same population as  Recruiting women with early onset  Recruiting wom

  20. Slide 20: Fetal Growth Restriction: DM199’s Indication Expansion

    Fetal Growth Restriction: DM199’s Indication Expansion Strong mechanistic rationale based on Interim Part 1a PE data 〉Fetal Growth Restriction is a Major Unmet Medical 〉DM199 Offers the Potential to Improve Challenge Uteroplacental Blood Flow – Placental insufficiency—particularly impaired – Like pr

  21. Slide 21: Thank You!

    Thank You! Nasdaq: dmac www.diamedica.com © 2025 DiaMedica Therapeutics. All Rights Reserved. 21

DiaMedica Therapeutics — Technical Presentation (July 2025) on 6ix